May 22 (Reuters) - Biocon Ltd BION.NS :
* HEALTH CANADA APPROVES MYLAN AND BIOCON'S OGIVRI™, THE FIRST TRASTUZUMAB BIOSIMILAR, FOR THE TREATMENT OF HER2-POSITIVE BREAST AND GASTRIC CANCERS
* MYLAN - PLANS TO LAUNCH OGIVRI THIS QUARTER
May 22 (Reuters) - Biocon Ltd BION.NS :
* HEALTH CANADA APPROVES MYLAN AND BIOCON'S OGIVRI™, THE FIRST TRASTUZUMAB BIOSIMILAR, FOR THE TREATMENT OF HER2-POSITIVE BREAST AND GASTRIC CANCERS
* MYLAN - PLANS TO LAUNCH OGIVRI THIS QUARTER